Sanger sequencing is the superior method for sequencing, and it is a process of incorporation of chain-terminating dideoxynucleotides by DNA polymerase during in vitro DNA replication. Sanger sequencing is known to provide high accuracy, long-read capabilities, and adaptability to support a diverse range of applications in many research areas. Sanger sequencing is mainly recognized for DNA sequencing and supports applications in RNA sequencing and epigenetic analysis.
To Know More About this Study Go Through Our Sample PDF
The List of Companies Profiling in this Study:
- Microsynth AG
- Laragen, Inc.
- StarSEQ GmbH
- Thermo Fisher Scientific, Inc.
- LGC Biosearch Technologies
- Fasteris SA
- Quintara Biosciences
- GENEWIZ
- GenScript
- SciGenom Labs
In many clinical studies, in different groups of subjects, substantive insights have been made by comparing the primary DNA sequences of genes. For example, As per Thermo Fisher Scientific, a recent study showed that up to 2% of the variants detected by NGS were not reproducible by Sanger sequencing. Therefore, in many clinical studies before a firm conclusion from variants identified by NGS, it should be confirmed by an orthogonal method. Reference materials sequenced by Sanger approaches provide ground truth against which the NGS assay can be benchmarked.
The healthcare industry aims to advanced technology to reduce health problems and to extend the lifespan of human beings. Therefore, international brands, as well as thousands of biotechnology start-ups across the globe, are aiming to contribute to humanity by developing new technologies for the healthcare sector.
Many of the evolving biotechnology and genetics start-ups are using DNA sequencing technologies for various applications. These new emerging companies are offering sequencing services that analyze human and animal genomes. For instance, located in Baltimore, United States, Personal Genome Diagnostics Inc. was founded in 2010 and is involved in genome analysis of human tumors. The company develops a patient-specific analysis of cancer by using sequencing tools and technologies.
Similarly, incorporated in 2011, Personalize offers genomic sequencing and analytics solutions and is also involved in next-generation cancer therapies depending on the patient’s genomic data. Thus the growing number of start-up companies entering the genome analysis industry is likely to fuel the market growth during the forecast period.
The Sanger sequencing service industry is expected to grow owing to factors such as increasing providers for Sanger sequencing services and growing applications of Sanger sequencing. Also, an increase in the number of startup companies for genome analysis is expected to have a positive impact on the growth of the market in the coming years.
Dinesh's Blog 